论文部分内容阅读
目的辛伐他汀对2型糖尿病患者氧化应激水平的干预效果。方法选取平顶山市第一人民医院2010年3月至2011年3月70例2型糖尿病患者患者为研究对象,将患者抽签随机分为观察组与对照组,每组35例。观察行辛伐他汀干预,对照组给予安慰剂,比较两组治疗前、后血清丙二醛(MDA)、超氧化物歧化酶(SOD)水平,总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、极低密度脂蛋白胆固醇(VLDL-C)等血脂水平。结果两组治疗前血清SOD及MDA水平比较无统计学意义(P>0.05);治疗后观察组血清SOD水平(91.46±9.68)n U/ml高于对照组(86.42±9.73)n U/ml,MDA水平(5.31±0.72)nmol/L低于对照组(7.55±0.73)nmol/L,有统计学意义(P<0.05)。观察组TC、TG、LDL-C、VLDL-C低于对照组,HDL-C高于对照组,有统计学意义(P<0.05)。结论辛伐他汀治疗2型糖尿病,可有效改善患者氧化应激水平,具有较好的调脂作用,对2型糖尿病的治疗具有重要的指导意义。
Objective To investigate the effect of simvastatin on oxidative stress in type 2 diabetic patients. Methods From January 2010 to March 2011, 70 patients with type 2 diabetes mellitus in First People’s Hospital of Pingdingshan City were selected as study subjects. Patients were randomized into observation group and control group with random sampling of 35 cases. The intervention of simvastatin was observed, while the control group was given placebo. The levels of malondialdehyde (MDA), superoxide dismutase (SOD), total cholesterol (TC), triglyceride (TG) , High-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and very low density lipoprotein cholesterol (VLDL-C) Results The levels of serum SOD and MDA in the two groups before treatment did not reach statistical significance (P> 0.05). After treatment, the level of serum SOD in the observation group was 91.46 ± 9.68 n U / ml higher than that in the control group (86.42 ± 9.73) n U / ml , And the MDA level (5.31 ± 0.72) nmol / L was lower than that of the control group (7.55 ± 0.73) nmol / L, with statistical significance (P <0.05). The levels of TC, TG, LDL-C and VLDL-C in the observation group were lower than those in the control group, and the levels of HDL-C in the observation group were higher than those in the control group (P <0.05). Conclusion Simvastatin treatment of type 2 diabetes can effectively improve the level of oxidative stress in patients with good lipid-lowering effect, which has important guiding significance for the treatment of type 2 diabetes.